Improved tumor targeting of anti-her2 nanobody through n-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling

Journal of Nuclear Medicine

Volumn 55, Issue 4, 2014, Pages 650-656

  Pruszynski, Marek ^a   Koumarianou, Eftychia ^a   Vaidyanathan, Ganesan ^a   Revets, Hilde ^b   Devoogdt, Nick ^c   Lahoutte, Tony ^c   Lyerly, H Kim ^a   Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ABLYNX NV   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Breast cancer; HER2; Nanobody; Radioiodination; SGMIB

Indexed keywords

DIAGNOSTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IODINE NANOBODY I 125; N (3 IODOBENZOATE) LYSINE N MALEIDO GLYCINE GEEEK NANOBODY I 125; N (3 IODOBENZOATE) LYSINE N MALEIDO GLYCINE GEEEK NANOBODY I 131; N SUCCINIMIDYL 4 GUANIDINOMETHYL 3 IODOBENZOATE NANOBODY I 125; N SUCCINIMIDYL 4 GUANIDINOMETHYL 3 IODOBENZOATE NANOBODY I 131; NANOBODY; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY LABELING; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; BREAST CANCER CELL LINE; BREAST CARCINOMA; CANCER DIAGNOSIS; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG DISTRIBUTION; DRUG EFFICACY; FEMALE; INTERNALIZATION; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; RADIOIODINATION; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

BREAST CANCER; HER2; NANOBODY; RADIOIODINATION; SGMIB;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BENZOATES; BREAST NEOPLASMS; FEMALE; GUANIDINE; HUMANS; ISOTOPE LABELING; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; SINGLE-DOMAIN ANTIBODIES; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901292894     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.127100     Document Type: Article

References (40)

1. Agus DB, Bunn PA, FranklinW, Garcia M, Ozols FR. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol. 2000;27:53-63.
2. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341-354.
3. Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. J Natl Cancer Inst. 2009;101:1306-1307.
4. Baselga J. Clinical trials of Herceptin (trastuzumab). Eur J Cancer. 2001;37 (suppl 1):18-24.
5. Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005;23:2534-2543.
6. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012;30:2585-2592.
7. Akabani G, Carlin S, Welsh P, Zalutsky MR. In vitro cytotoxicity of 211Atlabeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. Nucl Med Biol. 2006;33:333-347.
8. Persson M, Gedda L, Lundqvist H, et al. [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. Cancer Res. 2007;67:326-331.
9. Olafsen T, Kenanova VE, Sundaresan G, et al. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res. 2005;65:5907-5916.
10. Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Stahl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010;584:2670-2680.
11. Ren G, Zhang R, Liu Z, et al. A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression. J Nucl Med. 2009;50:1492-1499.
12. Vaneycken I, Devoogdt N, Van Gassen N, et al. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J. 2011;25:2433-2446.
13. Muyldermans S, Baral TN, Cortez-Retamozzo V, et al. Camelid immunoglobulins and nanobody technology. Vet Immunol Immunopath. 2009;128:178-183.
14. Revets H, De Baetselier P, Muyldermans S. Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther. 2005;5:111-124.
15. D'Huyvetter M, Aerts A, Xavier C, et al. Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators. Contrast Media Mol Imaging. 2012;7:254-264.
16. Pruszynski M, Koumarianou E, Vaidyanathan G, et al. Targeting breast carcinoma with radioiodinated anti-HER2 nanobody. Nucl Med Biol. 2013;40:52-59.
17. Gainkam LOT, Caveliers V, Devoogdt N, et al. Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. Contrast Media Mol Imaging. 2011;6:85-92.
18. Vaidyanathan G, Jestin E, Olafsen T, Wu AM, Zalutsky MR. Evaluation of an anti-p185HER2 (scFv-CH2-CH3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK. Nucl Med Biol. 2009;36:671-680.
19. De Santes K, Slamon D, Anderson SK, et al. Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res. 1992;52:1916-1923.
20. Vaidyanathan G, Affleck DJ, Bigner DD, Zalutsky MR. Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate. Nucl Med Biol. 2002;29:1-11.
21. Shankar S, Vaidyanathan G, Affleck DJ, Peixoto K, Bigner DD, Zalutsky MR. Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent. Nucl Med Biol. 2004;31:909-919.
22. Foulon CF, Welsh PC, Bigner DD, Zalutsky MR. Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR. Nucl Med Biol. 2001;28:769-777.
23. Vaidyanathan G, Alston KL, Bigner DD, Zalutsky MR. Ne-(3-[I]iodobenzoyl)- Lys5-Na-maleimido-Gly1-GEEEK ([I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies. Bioconjug Chem. 2006;17:1085-1092.
24. Vaidyanathan G, Zalutsky MR. Synthesis of N-succinimidyl 4-guanidinomethyl-3-[I]iodobenzoate: a radioiodination agent for labeling internalizing proteins and peptides. Nat Protoc. 2007;2:282-286.
25. Yu Z, Xia W, Wang H-Y, et al. Antitumor activity of an Ets protein, PEA3, in breast cancer cell linesMDA-MB-361DYT2andBT474M1.MolCarcinog. 2006;45:667-675.
26. Zahnd C, Kawe M, Stumpp MT, et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res. 2010;70:1595-1605.
27. Shankar S, Vaidyanathan G, Kuan C-T, Bigner DD, Zalutsky MR. Anti-epidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance. Nucl Med Biol. 2006;33:101-110.
28. Foulon CF, Reist CJ, Bigner DD, Zalutsky MR. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. Cancer Res. 2000;60:4453-4460.
29. Moshakis V, McIlhinney RA, Raghavan D, Neville AM. Localization of human tumour xenografts after i.v. administration of radiolabelled monoclonal antibodies. Br J Cancer. 1981;44:91-99.
30. Xavier C, Vaneycken I, D'Huyvetter M, et al. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 nanobodies for iPET imaging of HER2 receptor expression in cancer. J Nucl Med. 2013;54:776-784.
31. Vosjan MJ, Perk LR, Roovers RC, et al. Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET. Eur J Nucl Med Mol Imaging. 2011;38:753-763.
32. Heskamp S, Laverman P, Rosik D, et al. Imaging of human growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer. J Nucl Med. 2012;53:146-153.
33. Vegt E, De Jong M, Wetzels JFM, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010;51:1049-1058.
34. Stein R, Govindan SV, Mattes MJ, et al. Improved iodine radiolabels for monoclonal antibody therapy. Cancer Res. 2003;63:111-118.
35. Tugyi R, Uray K, Iván D, Fellinger E, Perkins A, Hudecz F. Partial D-amino acid substitution: improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide. Proc Natl Acad Sci USA. 2005;102:413-418.
36. Mather SJ, McKenzie AJ, Sosabowski JK, Morris TM, Ellison D, Watson SA. Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med. 2007;48:615-622.
37. Ekblad T, Tran T, Orlova A, et al. Development and preclinical characterization of 99mTc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging. 2008;35:2245-2255.
38. Verrey F, Ristic Z, Romeo E, et al. Novel renal amino acid transporters. Annu Rev Physiol. 2005;67:557-572.
39. Schuldt S, Carter P, Welbourne T. Glutamate transport asymmetry and metabolism in the functioning kidney. Am J Physiol. 1999;277:E439-E446.
40. Vaidyanathan G, Affleck DJ, Bigner DD, Zalutsky MR. N-succinimidyl 3-[211At] astato-4-guanidino-methylbenzoate: an acylation agent for labeling internalizing antibodies with a-particle emitting 211At. Nucl Med Biol. 2003;30:351-359.